Head-to-head · WeighScore
Embody vs TRYM Health
By GLP-1 ScorecardUpdated
Score comparison
Embody has the higher recorded score — 76.5/100 to 70.6/100.
Embody grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Embody is a low-cost injection option, but the modest prepaid savings deserve a close look beside its payment-finality and renewal rules.
Before you choose
Before comparing the headline prices, the Embody review and the TRYM Health review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Embody vs Vitara RX and Harbor vs TRYM Health compare each of them with another graded program, and the list of alternatives to Embody ranks the programs closest to Embody on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Embody | TRYM Health |
|---|---|---|
| WeighScore | 76.5/100 | 70.6/100 |
| Grade | C | C |
| Site position | #52 | #114 |
| Semaglutide | $79/mo (monthly plan; twelve-month bundle listed at $49/mo, upfront charge unpublished) | $96/mo (all doses, compounded) |
| Tirzepatide | $129/mo (monthly plan; twelve-month bundle listed at $99/mo, upfront charge unpublished) | $126/mo (all doses, compounded) |
| Coverage | State eligibility not fully published; confirm your location | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Monthly plans at $79 semaglutide and $129 tirzepatide in the published terms
- Separate monthly, three-, six- and twelve-month price tiers published
- OpenLoop care network and four pharmacy partners publicly named; individual assignment still needs confirmation
What to consider
- Payments are described as final at purchase except provider-initiated medical disqualification, with used services deducted
- Cancel at least 72 hours before renewal; unused prepaid months are not routinely refundable
- Homepage week counts differ from product month labels; confirm supply and charge dates
- Current catalog supports injections; no active oral-gum offer or universal state footprint confirmed
FDAWarning letter issued to TRYM Health, Inc. dba TRYM Health in September 2025. See the FDA warning-letter database.
Strengths
- Affordable compounded GLP-1 — semaglutide ~$96/mo ($3.20/day) and tirzepatide ~$126/mo ($4.20/day)
- Available in all 50 states with free shipping and FSA/HSA eligibility
- Multi-dose vials cover all doses up to the maximum; additive-free, with a full starter kit
- Temperature-controlled insulated shipping and flexible cancellation
What to consider
- Compounding pharmacy partner not named
- LegitScript certification was not documented on the public pages reviewed
- Lowest per-day pricing likely requires a longer prepaid plan commitment
- Drugs labeled generically as 'GLP-1' / 'GLP-1 + GIP' on the services page rather than named
- FDA issued TRYM Health, Inc. dba TRYM Health a warning letter in September 2025; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.